[-葡萄糖共运输体2型抑制剂对左心室扩张功能的影响:现状和前景]
E V Borisova1, A V Barsukov2, S A Glebova3
1KardioKlinica St Petersburg; Mechnikov North-Western State Medical University, St. Petersburg.
Kardiologiia
|August 5, 2024
概括
-葡萄糖携带转运体-2 抑制剂 (SGLT2 抑制剂) 改善了心力衰竭患者的心脏功能,并保留了喷射分数 (HFpEF). 这些心血管药物通过各种细胞内机制对左心室透静功能产生积极影响.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭通常表现为左心室扩张功能 (DF) 的损伤.
- -葡萄糖共运输体-2 (SGLT2) 抑制剂,也称为gliflozins,代表了一种新的心血管药物类别,显示出显著的临床疗效.
- SGLT2 抑制剂对 HFpEF 患者的预后产生有益影响.
研究的目的:
- 调查SGLT2抑制剂扩张性作用背后的细胞内机制.
- 评估SGLT2抑制剂对HFpEF中左心室扩张功能的影响.
- 探索草甘的抗炎和抗氧化特性在改善心肌细胞DF中的作用.
主要方法:
- 使用HFpEF的实验室模型进行实验研究.
- 对心肌细胞肌纤维弹性,心肌纤维化动态和细胞内/平衡的影响分析.
- 评估SGLT2抑制剂对高风险患者LV DF的影响的临床研究的综述.
主要成果:
- 在实验HFpEF模型中,达帕格利弗洛辛和恩帕格利弗洛辛对心肌细胞纤维丝弹性,纤维化和离子稳态产生了积极影响.
- 草甘的抗炎和抗氧化特性有助于改善心肌细胞DF.
- 临床研究表明,SGLT2抑制剂对心肌放松有保护作用,并可能导致LV透静功能障碍的回归.
结论:
- 在HFpEF中,SGLT2抑制剂对左心室扩张功能表现出有希望的效果.
- SGLT2抑制剂对HFpEF预后的有益影响得到实验和临床证据的支持.
- 对SGLT2抑制剂的心脏特异性机制进行进一步研究是有必要的.
相关概念视频
01:27Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
01:55Secondary Active Transport
118.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
118.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:26Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
720
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720
01:24Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311